Views 683
Citations 0
Editor's Note
January 2016

Finding the Right Price for Improving Care

Author Affiliations

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2016;176(1):109. doi:10.1001/jamainternmed.2015.7230

The US Food and Drug Administration (FDA) recently approved alirocumab and evolocumab, 2 monoclonal antibody PCSK9 inhibitors that reduce low-density lipoprotein cholesterol. In this edition of JAMA Internal Medicine, Tice et al1 of the Institute for Clinical and Economic Review (ICER) provide a systematic review of the efficacy, safety, and costs of these therapies. These drugs seem to be effective and safe; however, most included trials lasted fewer than 6 months, and none used cardiovascular events as a primary outcome. A meta-analysis of these trials estimates a 50% relative risk reduction of cardiovascular mortality; however, because of the meta-analysis’s limitations, the actual effect on mortality will not be characterized until ongoing trials conclude in 2017.

First Page Preview View Large
First page PDF preview
First page PDF preview